Jan 15, 2025 9:15am EST TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
Dec 19, 2024 9:15am EST TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Dec 09, 2024 9:00am EST TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
Oct 02, 2024 9:10am EDT TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
Aug 21, 2024 9:00am EDT TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
Jul 24, 2024 9:05am EDT TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
Jul 22, 2024 9:00am EDT MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
Jun 17, 2024 9:00am EDT MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
Mar 05, 2024 9:15am EST MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
